Clinical trial
Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In…
NCT00320385 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00320385 |
|---|---|
| Title | Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer |
| Official title | A Randomized, Multicenter, Open-Label, Phase III Study of Lapatinib in Combination With Trastuzumab Versus Lapatinib Monotherapy in Subjects With HER2-positive Metastatic Breast Cancer Whose Disease Has Progressed on Trastuzumab-Containing Regimens |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Neoplasms, Breast |
| Intervention type | Biological, Drug |
| Interventions | Lapatinib, Trastuzumab |
| Enrollment | 296 |
| Start date | Nov 1, 2005 |
| Primary completion | Jun 1, 2007 |
| Completion | Oct 1, 2010 |
| First posted | May 3, 2006 |
| Last update posted | Feb 26, 2016 |
| Countries | Austria, Bulgaria, Canada, Croatia, Czechia, Finland, Germany, Greece, Italy, Poland, Spain, United Kingdom and 1 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: